Skip to content

Polaryx Therapeutics, Inc. PLYX Stock Issuance Proceeds

Stock Issuance Proceeds at other companies

Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
$752K
Eton Pharmaceuticals, Inc. logo
Eton Pharmaceuticals, Inc.ETON
$1.39M+253%
XER
Xeris Biopharma Holdings, Inc.XERS
$847K-82.6%
PVL
Palvella TherapeuticsPVLA
$230M
Acadia Pharmaceuticals logo
Acadia PharmaceuticalsACAD
$4.23M+130%
PTC Therapeutics logo
PTC TherapeuticsPTCT
$6.4M-59.3%

Other financials

Income statement

See full
Operating income-$2.0M+61.2%
Net income-$2.5M+49.6%
EPS (diluted)-$0.05+54.5%

Balance sheet

See full
Cash & equivalents$3.1M+1,132%
Total equity$2.5M-41.5%
Total assets$3.5M

Cash flow

See full
Operating cash flow-$2.1M-191%

Valuation

See full
Market cap$132.59M-86.9%

Returns & leverage

See full
Return on equity-1,209.8%
Current ratio3.5×

Where this comes from

Reported directly by Polaryx Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceOfCommonStock.

The official record: Polaryx Therapeutics, Inc. ’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Polaryx Therapeutics, Inc. 's stock issuance proceeds.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Polaryx Therapeutics, Inc. 's stock issuance proceeds?
Polaryx Therapeutics, Inc. (PLYX) reported stock issuance proceeds of $250K in Q1 2025.
How has Polaryx Therapeutics, Inc. 's stock issuance proceeds changed year-over-year?
Polaryx Therapeutics, Inc. 's stock issuance proceeds decreased by 86.3% year-over-year, from $1.83M to $250K.
What does stock issuance proceeds mean?
Cash received from issuing common stock — IPOs, secondary offerings, DRIP, employee stock purchase plans, and option exercises.